Any current/future new fundraising through debt or equity?

The company has taken on additional long-term borrowing (an increase of INR5 crore) in the form of a term loan from current bankers. This borrowing is meant to fund the ongoing capex plan, including facility upgrades in Haridwar, setting up R&D labs, and construction activities. There is no explicit mention of any planned new equity fundraising. The focus appears to be on organic growth supported by internal capex and operational improvements rather than fresh equity infusion. No specific details were shared about future debt or equity fundraising beyond the current term loan for capex.

Any current/future capex/capital investment/strategic investment?

FY23 capex totaled around INR 29 crores (net of depreciation), invested in: - Upgrading Haridwar facility (~INR 14.65 crores) for EU GMP compliance and additional injectable lines. - Enhancing Vapi factory capacity (~INR 11 crores). - Increasing R&D base in Hyderabad and setting up a new R&D lab in Baroda (~INR 1.17 crores). - Plant and machinery additions and building construction for refinement projects. Capex funded partly through increased long-term borrowing (~INR 5 crores term loan). Focus on strategic investments to support growth areas: - Injectable line upgrades and obtainin

Future growth expectations in sales/revenue/volumes?

Themis Medicare expects a 35% CAGR growth over the next 2-3 years, driven primarily by hospital business expansion. Growth in hospital business is supported by building and adding specialized sales teams focused on hospitals. New product launches, including generics for emerging markets and new drug delivery systems, are planned but will take time due to regulatory approvals. The critical care portfolio is being developed steadily, with plans to introduce more teams and products over the next 3-4 years. Export markets remain a focus, targeting 40+ emerging markets with high-value generics. API

Future growth expectations in earnings/operating earnings/profits/EPS?

Themis Medicare expects a 35% CAGR growth over the next two to three years, driven primarily by hospital business expansion and improved productivity. EBITDA margin target is above 25%, up from the current ~19%; management anticipates achieving this as new teams become productive without a significant increase in fixed costs. PAT margin was 16.06% for FY23, with expectations for improvement as operational efficiencies and margin management improve. EPS for FY23 stood at Rs.61.83, with growth expected alongside revenue and margin expansion. Revenue growth is anticipated to pick up after a COVID

Current/ Expected Orderbook/ Pending Orders?

The transcript does not provide specific figures or qualitative details about the current or expected order book or pending orders for Themis Medicare Limited. It mentions significant COVID-related orders in the previous year (FY22), amounting to around INR 60 crores, which were not present in the current year (FY23). The company expects growth driven by hospital business expansion and new product launches. Management is focusing on building the hospital business and increasing sales productivity but no direct reference to order book size or pending order values is provided. Incremental margi

Themis Medicare LtdQ4 FY23Pharmaceuticals & Biotechnology

Themis Medicare Ltd Q4 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹113Market Cap: ₹1.1K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 2

Themis Medicare expects a 35% CAGR growth over the next 2-3 years, driven primarily by hospital business expansion.
Growth in hospital business is supported by building and adding specialized sales teams focused on hospitals.
New product launches, including generics for emerging markets and new drug delivery systems, are planned but will take time due to regulatory approvals.
The critical care portfolio is being developed steadily, with plans to introduce more teams and products over the next 3-4 years.
Export markets remain a focus, targeting 40+ emerging markets with high-value generics.
API business is expected to show improvement with a new manufacturing process.
Domestic formulation business aims for first-launch opportunities with improved margins.
Overall growth will leverage increased productivity without a significant rise in fixed sales force costs.

Margin guidance

Category 1

Themis Medicare expects a 35% CAGR growth over the next two to three years, driven primarily by hospital business expansion and improved productivity.
EBITDA margin target is above 25%, up from the current ~19%; management anticipates achieving this as new teams become productive without a significant increase in fixed costs.
PAT margin was 16.06% for FY23, with expectations for improvement as operational efficiencies and margin management improve.
EPS for FY23 stood at Rs.61.83, with growth expected alongside revenue and margin expansion.
Revenue growth is anticipated to pick up after a COVID-related high base in the previous year, with recovery to 20% EBITDA margins expected by H1 of the financial year.
Margin improvements will also come from better API cost structures and hospital business scaling.

See what Themis Medicare Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

The company has taken on additional long-term borrowing (an increase of INR5 crore) in the form of a term loan from current bankers.
This borrowing is meant to fund the ongoing capex plan, including facility upgrades in Haridwar, setting up R&D labs, and construction activities.
There is no explicit mention of any planned new equity fundraising.
The focus appears to be on organic growth supported by internal capex and operational improvements rather than fresh equity infusion.
No specific details were shared about future debt or equity fundraising beyond the current term loan for capex.

Order book

The transcript does not provide specific figures or qualitative details about the current or expected order book or pending orders for Themis Medicare Limited.
It mentions significant COVID-related orders in the previous year (FY22), amounting to around INR 60 crores, which were not present in the current year (FY23).
The company expects growth driven by hospital business expansion and new product launches.
Management is focusing on building the hospital business and increasing sales productivity but no direct reference to order book size or pending order values is provided.
Incremental margin improvement is expected primarily from improved sales productivity rather than increased order volume disclosed.
Overall, no explicit current or expected orderbook or pending order quantifications are shared in this transcript.

See what Themis Medicare Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

FY23 capex totaled around INR 29 crores (net of depreciation), invested in:
- Upgrading Haridwar facility (~INR 14.65 crores) for EU GMP compliance and additional injectable lines.
- Enhancing Vapi factory capacity (~INR 11 crores).
- Increasing R&D base in Hyderabad and setting up a new R&D lab in Baroda (~INR 1.17 crores).
- Plant and machinery additions and building construction for refinement projects.
Capex funded partly through increased long-term borrowing (~INR 5 crores term loan).
Focus on strategic investments to support growth areas:
- Injectable line upgrades and obtaining UDMP certification to open export opportunities.
- Building critical care product portfolio aligned with hospital business focus.
- Strengthening R&D with skilled manpower and infrastructure to drive future product development.
Future investments expected to support expansion in hospital and API businesses, with a cautious approach to fixed costs.

Track Themis Medicare Ltd — get its next earnings analysis in your feed

How does Themis Medicare Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisThemis Medicare Ltd

Rev 2Mar 1

See where Themis Medicare Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Themis Medicare Ltd rank in Pharmaceuticals & Biotechnology?

Compare Themis Medicare Ltd against every Pharmaceuticals & Biotechnology company (Q4 FY23) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Themis Medicare Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →